Abstract
Recently, with the widespread implementation of “Real-World Data (RWD),” there is increasing interest in using high-quality administrative claims, laboratory tests, electronic health records (EHRs), and information-sharing resources to enhance detection of serious adverse drug reactions (ADRs).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jensen PB, Jensen LJ, Brunak S (2012) Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet 13(6):395–405
Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R (2011) Developing the sentinel system—a national resource for evidence development. N Engl J Med 458 364(6):498–499
Yamada K, Itoh M, Fujimura Y, Kimura M, Murata K, Nakashima N, Nakayama M, Ohe K, Orii T, Sueoka E, Suzuki T, Yokoi H, Ishiguro C, Uyama Y (2019) MID-NET® project group. The utilization and challenges of Japan’s MID-NET® medical information database network in post marketing drug safety assessments: a summary of pilot pharmacoepidemiological Studies. Pharmacoepidemiol Drug Saf 28(5):601–608
Yamaguchi M, Inomata S, Harada S, Matsuzaki Y, Kawaguchi M, Ujibe M, Kishiba M, Fujimura Y, Kimura M, Murata K, Nakashima N, Nakayama M, Ohe K, Orii T, Sueoka E, Suzuki T, Yokoi H, Takahashi F, Uyama Y (2019) Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol Drug Saf 28(10):1395–1404
Matoba T, Kohro T, Fujita H, Nakayama M, Kiyosue A, Miyamoto Y, Nishimura K, Hashimoto H, Antoku Y, Nakashima N, Ohe K, Ogawa H, Tsutsui H, Nagai R (2019) Architecture of the Japan ischemic heart disease multimodal prospective data acquisition for precision treatment (J-IMPACT) system. Int Heart J 60(2):264–270
Nakashima N (2016) Pharmaceutical regulatory harmonization and evaluation research project “Practical analysis method and education on drug epidemiology research for benefits and risk assessment of pharmaceuticals using MID-NET”. The Japan agency for medical research and development (AMED) outsourced research and development results report [Grant Number: 15mk0101014h0102] [Japanese]
The World Health Organization (WHO) (2017) ICD-10 version (classification of diseases)
Kaihara S, Takekuma R, Tsuchiya F (2002) Standard master for pharmaceutical products (HOT reference number). JAMI 22(4):315–319
Ministry of Health, Labour and Welfare (2019) List of drug prices and information on generic drugs [Japanese] [internet] [cited Nov 09, 2019]. Available from: https://www.mhlw.go.jp/topics/2019/08/tp20190819-01.html
The Japan Society of Laboratory Medicine (2019) The Japan laboratory accreditation cooperation (JLAC) 10 [internet] [cited Feb 18, 2019]. Available from: https://www.jslm.org/committees/code/index.html
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
There is no conflict of interest to declare.
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Park, J. (2022). Data Quality Governance Experience at the MID-NET Project. In: Nakashima, N. (eds) Epidemiologic Research on Real-World Medical Data in Japan. SpringerBriefs for Data Scientists and Innovators, vol 2. Springer, Singapore. https://doi.org/10.1007/978-981-19-1622-9_7
Download citation
DOI: https://doi.org/10.1007/978-981-19-1622-9_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-1621-2
Online ISBN: 978-981-19-1622-9
eBook Packages: MedicineMedicine (R0)